Ventyx Biosciences, Inc. Financials
This page shows Ventyx Biosciences, Inc. (VTYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ventyx Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Ventyx Biosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Ventyx Biosciences, Inc. reported a net loss of $135.1M while operations used $130.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ventyx Biosciences, Inc.'s EBITDA was -$148.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.7% from the prior year.
Ventyx Biosciences, Inc. reported -$135.1M in net income in fiscal year 2024. This represents an increase of 30.0% from the prior year.
Ventyx Biosciences, Inc. earned -$1.97 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.3% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Ventyx Biosciences, Inc. recorded an outflow of $131.1M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents an increase of 21.5% from the prior year.
Ventyx Biosciences, Inc. held $27.3M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Margins & Returns
Ventyx Biosciences, Inc.'s ROE was -53.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 25.9 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Ventyx Biosciences, Inc. invested $117.0M in research and development in fiscal year 2024. This represents a decrease of 33.4% from the prior year.
Ventyx Biosciences, Inc. invested $241K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 53.1% from the prior year.
Not reported for fiscal year 2024.
VTYX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $117.0M-33.4% | $175.8M+100.3% | $87.7M+50.0% | $58.5M | N/A |
| SG&A Expenses | N/A | $31.4M-2.4% | $32.2M+26.9% | $25.4M+193.1% | $8.7M+1167.0% | $684K |
| Operating Income | N/A | -$148.4M+28.6% | -$208.0M-83.8% | -$113.1M-68.5% | -$67.1M | N/A |
| Net Income | N/A | -$135.1M+30.0% | -$193.0M-78.0% | -$108.4M-29.5% | -$83.7M | N/A |
| EPS (Diluted) | — | -$1.97+40.3% | -$3.30-59.4% | -$2.07 | -$6.65 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTYX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Total Assets | $276.6M-0.4% | $277.7M-25.2% | $371.4M+27.4% | $291.5M+118872.2% | $245K |
| Current Assets | $229.6M-13.1% | $264.3M-20.1% | $330.7M+25.7% | $263.0M+107255.1% | $245K |
| Cash & Equivalents | $27.3M-47.1% | $51.6M-20.4% | $64.8M-8.4% | $70.8M+28912.7% | $244K |
| Total Liabilities | $22.5M-33.3% | $33.8M+92.9% | $17.5M+42.5% | $12.3M-60.2% | $30.9M |
| Current Liabilities | $12.8M-42.6% | $22.3M+36.1% | $16.4M+33.2% | $12.3M+775.5% | $1.4M |
| Total Equity | $254.0M+4.1% | $243.9M-31.1% | $353.9M+26.8% | $279.2M+1010.8% | -$30.7M |
| Retained Earnings | -$554.3M-32.2% | -$419.2M-85.3% | -$226.2M-92.0% | -$117.8M-262.4% | -$32.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
VTYX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$87.8M | -$130.9M+21.4% | -$166.5M-68.6% | -$98.8M-155.6% | -$38.6M | N/A |
| Capital Expenditures | $114K | $241K-53.1% | $514K+86.9% | $275K+5.0% | $262K | N/A |
| Free Cash Flow | -$87.9M | -$131.1M+21.5% | -$167.0M-68.6% | -$99.0M-154.5% | -$38.9M | N/A |
| Investing Cash Flow | $57.7M | -$15.5M-115.4% | $100.9M+234.7% | -$74.9M+65.0% | -$214.4M | N/A |
| Financing Cash Flow | N/A | $122.1M+129.0% | $53.3M-68.2% | $167.8M-48.1% | $323.6M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTYX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Return on Equity | -53.2%+25.9pp | -79.1%-48.5pp | -30.6%-0.6pp | -30.0% | N/A |
| Return on Assets | -48.9%+20.6pp | -69.5%-40.3pp | -29.2%-0.5pp | -28.7% | N/A |
| Current Ratio | 17.97+6.1x | 11.87-8.3x | 20.21-1.2x | 21.41+21.2x | 0.17 |
| Debt-to-Equity | 0.090.0x | 0.14+0.1x | 0.050.0x | 0.04 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Ventyx Biosciences, Inc. Ranks
Frequently Asked Questions
Is Ventyx Biosciences, Inc. profitable?
No, Ventyx Biosciences, Inc. (VTYX) reported a net income of -$135.1M in fiscal year 2024.
What is Ventyx Biosciences, Inc.'s EBITDA?
Ventyx Biosciences, Inc. (VTYX) had EBITDA of -$148.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ventyx Biosciences, Inc.'s return on equity (ROE)?
Ventyx Biosciences, Inc. (VTYX) has a return on equity of -53.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Ventyx Biosciences, Inc.'s free cash flow?
Ventyx Biosciences, Inc. (VTYX) recorded an outflow of $131.1M in free cash flow during fiscal year 2024. This represents a 21.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ventyx Biosciences, Inc.'s operating cash flow?
Ventyx Biosciences, Inc. (VTYX) recorded an outflow of $130.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Ventyx Biosciences, Inc.'s total assets?
Ventyx Biosciences, Inc. (VTYX) had $276.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ventyx Biosciences, Inc.'s capital expenditures?
Ventyx Biosciences, Inc. (VTYX) invested $241K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ventyx Biosciences, Inc. spend on research and development?
Ventyx Biosciences, Inc. (VTYX) invested $117.0M in research and development during fiscal year 2024.
What is Ventyx Biosciences, Inc.'s current ratio?
Ventyx Biosciences, Inc. (VTYX) had a current ratio of 17.97 as of fiscal year 2024, which is generally considered healthy.
What is Ventyx Biosciences, Inc.'s debt-to-equity ratio?
Ventyx Biosciences, Inc. (VTYX) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ventyx Biosciences, Inc.'s return on assets (ROA)?
Ventyx Biosciences, Inc. (VTYX) had a return on assets of -48.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ventyx Biosciences, Inc.'s cash runway?
Based on fiscal year 2024 data, Ventyx Biosciences, Inc. (VTYX) had $27.3M in cash against an annual operating cash burn of $130.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Ventyx Biosciences, Inc.'s Piotroski F-Score?
Ventyx Biosciences, Inc. (VTYX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ventyx Biosciences, Inc.'s earnings high quality?
Ventyx Biosciences, Inc. (VTYX) reported a net loss of $135.1M while operations used $130.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.